Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

An Immune Senescence and Exhaustion-Related RNA Profile Predicts Clinical Outcomes in Acute Myeloid Leukemia

Jayakumar Vadakekolathu, PhD, Tung On Yau, Heidi Altmann, PhD, Sarah E. Church, PhD, Hanna A Knaus, MD, Mark D. Minden, Jan K Davidson-Moncada, MDPhD, Sarah K Tasian, MD, Martin Bornhäuser, MD, Ivana Gojo, MD, Leo Luznik, MD, Sergio Rutella, MDPhDFRCPath

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-134779

Published: 2020

Journal Articles

A Signature of T Cell Exhaustion Is Enriched in the Bone Marrow (BM) of AML Patients and Shared with Immune Exhaustion Signatures of Solid Tumors

Hanna A. Knaus, MD, Hubert Hackl, Amanda Blackford, Sofia Berglund, Raul Montiel-Esparza, Joshua F Zeidner, MD, Ivana Gojo, MD, Leo Luznik, MD

Blood (2019) 134 (Supplement_1): 2711.

https://doi.org/10.1182/blood-2019-128742

Published: 2019

Journal Articles

Acute Myeloid Leukemia (AML) Blasts Influence the Gene Expression Signature and Co-Signaling Receptor Expression of CD8 + T Cells

Hanna A. Knaus, MD, Sofia Berglund, MD PhD, Hubert Hackl, PhD, Raúl Montiel-Esparza, MD, Mark J. Levis, MD PhD, Judith E Karp, MD, Ivana Gojo, MD, Leo Luznik, MD

Blood (2016) 128 (22): 1700.

https://doi.org/10.1182/blood.V128.22.1700.1700

Published: 2016

Journal Articles

Phase 1 Study of Pomalidomide Given at the Time of Early Lymphocyte Recovery after Induction Timed Sequential Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS)

Blood (2016) 128 (22): 2820.

https://doi.org/10.1182/blood.V128.22.2820.2820

Published: 2016

Journal Articles

Stabilization of Myelodysplastic Syndromes (MDS) Following Hypomethylating Agent (HMAs) Failure Using the Immune Checkpoint Inhibitor Ipilimumab: A Phase I Trial

Amer M. Zeidan, MBBS, MHS, Joshua F. Zeidner, MD, Amy Duffield, MD, Hanna A. Knaus, MD, Anna Ferguson, BSN, RN, Katherine Sheldon, Amy E. DeZern, MD MHS, Ivana Gojo, MD, Steven D. Gore, MD, Howard Streicher, MD, Leo Luznik, B. Douglas Smith

Blood (2015) 126 (23): 1666.

https://doi.org/10.1182/blood.V126.23.1666.1666

Published: 2015

Journal Articles

Immune Modulation with Pomalidomide after Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML)

Raúl Montiel-Esparza, MD, Hanna A. Knaus, MD, Joshua F. Zeidner, MD, Ante Vulic, MD, Gabrielle T. Prince, MD, B. Douglas Smith, MD, Mark J. Levis, MD PhD, Howard Streicher, MD, Judith E. Karp, MD, Leo Luznik, MD, Ivana Gojo, MD

Blood (2015) 126 (23): 1351.

https://doi.org/10.1182/blood.V126.23.1351.1351

Published: 2015

Journal Articles

Tracking Effector T Cell Dynamics and Immune Inhibitory Receptors in Patients with Acute Myeloid Leukemia (AML)

Hanna A. Knaus, MD, Raúl Montiel-Esparza, MD, Joshua F. Zeidner, MD, Amanda Blackford, ScM, Christopher G. Kanakry, MD, Ante Vulic, MD, Mark J. Levis, MD PhD, Judith E. Karp, MD, Leo Luznik, MD, Ivana Gojo, MD

Blood (2015) 126 (23): 3849.

https://doi.org/10.1182/blood.V126.23.3849.3849

Published: 2015

Journal Articles

Characterization of Immune Evasion Mechanisms at Diagnosis and after Chemotherapy in Patients with Acute Myeloid Leukemia

Hanna A. Knaus, MD, Joshua F. Zeidner, MD, Raul Montiel Esparza, MD, Christopher G. Kanakry, Sudipto Ganguly, PhD, Ante Vulic, MD, Amanda Blackford, MS, B. Douglas Smith, MD, Judith E. Karp, MD, Leo Luznik, MD, Ivana Gojo, MD

Blood (2014) 124 (21): 1065.

https://doi.org/10.1182/blood.V124.21.1065.1065

Published: 2014

NARROW

An Immune Senescence and Exhaustion-Related RNA Profile Predicts Clinical Outcomes in Acute Myeloid Leukemia

A Signature of T Cell Exhaustion Is Enriched in the Bone Marrow (BM) of AML Patients and Shared with Immune Exhaustion Signatures of Solid Tumors

Acute Myeloid Leukemia (AML) Blasts Influence the Gene Expression Signature and Co-Signaling Receptor Expression of CD8 + T Cells

Phase 1 Study of Pomalidomide Given at the Time of Early Lymphocyte Recovery after Induction Timed Sequential Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS)

Stabilization of Myelodysplastic Syndromes (MDS) Following Hypomethylating Agent (HMAs) Failure Using the Immune Checkpoint Inhibitor Ipilimumab: A Phase I Trial

Immune Modulation with Pomalidomide after Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML)

Tracking Effector T Cell Dynamics and Immune Inhibitory Receptors in Patients with Acute Myeloid Leukemia (AML)

Characterization of Immune Evasion Mechanisms at Diagnosis and after Chemotherapy in Patients with Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only